These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 32295735

  • 1. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V, Yikilmaz AS, Kilicarslan A, Bakanay SM, Akinci S, Dilek İ.
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L, Teixido C, Castrejon N, Climent F, Carrió A, Marginet M, Soldini D, González-Farré B, Ribera-Cortada I, Lopez-Guillermo A, González-Barca E, Sierra A, Herrera M, Gómez C, Garcia A, Balagué O, Campo E, Martinez A.
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [Abstract] [Full Text] [Related]

  • 3. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
    Özdemir S, Ton Ö, Kabukcuoğlu F.
    Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E, Kato S, Shimada K, Tanaka T, Suzuki Y, Satou A, Kohno K, Sakakibara A, Yamamura T, Nakamura M, Miyahara R, Goto H, Nakamura S, Hirooka Y.
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
    Hollander P, Ginman B, Molin D, Enblad G, Amini RM, Glimelius I.
    Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A, Shinozaki-Ushiku A, Kunita A, Kondo A, Ushiku T.
    Am J Surg Pathol; 2022 Oct 01; 46(10):1386-1396. PubMed ID: 35605962
    [Abstract] [Full Text] [Related]

  • 10. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N, Mahaprom K, Jiarpinitnun C, Trachu N, Tubthong N, Pattaranutaporn P, Sirachainan E, Ngamphaiboon N.
    Am J Clin Oncol; 2018 Dec 01; 41(12):1204-1210. PubMed ID: 29672367
    [Abstract] [Full Text] [Related]

  • 11. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X, Kong H, Luo L, Han S, Lei T, Yu H, Guo N, Li C, Peng S, Dong X, Yang H, Wu M.
    BMC Cancer; 2022 Jan 03; 22(1):9. PubMed ID: 34980000
    [Abstract] [Full Text] [Related]

  • 12. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S, Bağır E, Seydaoglu G, Ercolak V, Ergin M.
    Ann Hematol; 2015 Sep 03; 94(9):1545-52. PubMed ID: 26004934
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
    Nagpal P, Descalzi-Montoya DB, Lodhi N.
    Cancer Rep (Hoboken); 2021 Apr 03; 4(2):e1311. PubMed ID: 33103852
    [Abstract] [Full Text] [Related]

  • 17. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK.
    Virchows Arch; 2016 Nov 03; 469(5):581-590. PubMed ID: 27595782
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J, Yang X, Wang X, Luo Y, Zhou W, Luo H, Bianba Z, Nima Z, Wang Q, Wang H, Liao R, Ciren Q, Li M, Pang J.
    Biomed Res Int; 2022 Nov 03; 2022():2684065. PubMed ID: 35734348
    [Abstract] [Full Text] [Related]

  • 19. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG, Coberly J, Gupta A, John G, Naina H, Koduru P, Chen W.
    Ann Clin Lab Sci; 2021 Mar 03; 51(2):174-181. PubMed ID: 33941556
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.
    Jimenez O, Colli S, Garcia Lombardi M, Preciado MV, De Matteo E, Chabay P.
    Cancer Immunol Immunother; 2021 Jun 03; 70(6):1519-1526. PubMed ID: 33184699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.